Research Article
BibTex RIS Cite

Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması

Year 2019, Volume: 46 Issue: 3, 479 - 487, 16.09.2019
https://doi.org/10.5798/dicletip.620502

Abstract

Amaç: Asimetrik dimetilarginin (ADMA), nitrik oksit sentazın (NOS) ana endojen inhibitörüdür. NOS, konak savunmasında ve vasküler yapının sürdürülmesinde önemli rol oynamaktadır. Yüksek ADMA düzeylerinin endoteldis fonksiyonu ile ilişkili olduğu ve çeşitli hastalıklarda rol aldığı gösterilmiştir. Brucellaspp.’nin neden olduğu zoonoz bir hastalık olan bruselloz, vaskülopati olarak kendini gösterebilmektedir. Ancak, bruselloz ile ADMA arasındaki ilişki ile ilgili yeterli veri bulunmamaktadır. Çalışmamızın amacı bruselloz hastalarında ve kontrol grubunda ADMA düzeyinin araştırılmasıdır.
Yöntemler: Çalışmamıza 40 akut bruselloz hastası ve 40 sağlıklı gönüllü alındı. Bruselloz hastalarında ve sağlıklı gönüllülerde serum ADMA düzeyleri İnsan ADMA ELISA kiti ile üretici firma önerileri doğrultusunda araştırıldı. Katılımcıların fiziki muayeneleri yapılarak, cinsiyet, yaş ve ikamet adreslerini içeren demografik karakteristikleri ve laboratuvar test sonuçları kayıt altına alındı. Verilerin değerlendirilmesinde IBM SPSS 20 istatistik paket programı kullanıldı. İstatistiksel anlamlılık düzeyi (p<0.05) ve (p<0.01) olarak kabul edildi.
Bulgular: Çalışmaya alınan 40 akut brusellozlu hastanın 18'i (% 45) erkek, 22'si (% 55) kadındı ve yaş ortalaması 49.22 ± 17.33 idi. Kontrol grubundaki 40 sağlıklı gönüllünün 18'i (% 45) erkek, 22'si (% 55) kadındı ve yaş ortalaması 39.02 ± 7.88 idi. Serum ADMA düzeyleri bruselloz ve kontrol grubunda sırasıyla; 262.6±139.59 ng/ml ve 196.52±85.25 ng/ml olarak saptandı. Bruselloz grubunda, kontrol grubu ile karşılaştırıldığında istatistiksel olarak anlamlı bir farklılık tespit edildi (p=0.013).
Sonuç: Çalışmamızda bruselloz grubundaki hastalarda serum ADMA düzeyleri, kontrol grubuna göre anlamlı olarak yüksek bulundu. ADMA düzeylerindeki bu yüksekliğin, brusellozun vaskülitteki rolü konusunda yeni yorumlar yapılmasına olanak sağlanacağı ve yeni tedavi yöntemlerinin gündeme gelebileceği kanaatindeyiz.

References

  • 1. Böger RH, Ron ES. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev. 2005; 10: 14-23.
  • 2. Böger RH. The emerging role of asymmetric dimethyarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003; 59: 824-33.
  • 3. Cooke JP. ADMA: its role in vascular disease. Vasc Med. 2005; 10: 11-7.
  • 4. Sitar ME, Kayacelebi AA, Beckmann B, Kielstein JT, Tsikas D. Asymmetric dimethylarginine (ADMA) in human blood: effects of extended haemodialysis in the critically ill patient with acute kidney injury, protein binding to human serum albumin and proteolysis by thermolysin. Amino Acids. 2015; 47: 1983-93.
  • 5. Teerlink T. ADMA metabolism and clearance. Vasc Med. 2005; 10: 73-81.
  • 6. Tain YL, Hsu CN. Toxic Dimethylarginines: Asymmetric Dimethlyarginine (ADMA) and Symmetric Dimethylarginine (SDMA). Toxins (Basel). 2017; 9: 92.
  • 7. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl. 2003; 4: 41-51.
  • 8. Gwida M, Al Dahouk S, Melzer F, et all. Brucellosis – regionally emerging zoonotic disease? Croat Med J. 2010; 51: 289-95.
  • 9. El-Koumi MA, Afify M, Al-Zahrani SH. A prospective study of brucellosis in children: relative frequency of pancytopenia. Mediterr J Hematol Infect Dis. 2013; 5: e2013011.
  • 10. Dede G, Dede O, Kapmaz M, Haykır Solay A, Utangaç M. Two cases of brucellosis epididymo-orchitis. Dicle Med J. 2015; 42 : 80-82.
  • 11. Ulu-Kilic A, Metan G, Alp E. Clinical presentations and diagnosis of brucellosis. Recent Pat Antiinfect Drug Discov. 2013; 8: 34-41.
  • 12. Dizbay M, Hizel K, Kilic S, et all. Brucella peritonitis and leucocytoclastic vasculitis due to Brucella melitensis. Braz J Infect Dis. 2007; 11: 443-44.
  • 13. Karahocagil MK, Aslan M, Ceylan MR, et all. Serum myeloperoxidase activity and oxidative stress in patients with acute brucellosis. Clin Biochem. 2012; 45: 733-6.
  • 14. Smith CL, Anthony S, Hubank M, Leiper JM, Vallance P. Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. PLoS Med. 2005; 2: e264.
  • 15. Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des. 2008; 14: 2613-8.
  • 16. Weis M, Kledal TN, Lin KY, et all. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation. 2004; 109: 500-5.
  • 17. Karakecili F, Cikman A, Aydin M, Gulhan B. Asymmetrical dimethylarginine levels in Hepatitis B virus-positive patients. Ann Lab Med. 2018; 38: 446-9.
  • 18. Kurz K, Teerlink T, Sarcletti M, et all. Asymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral theraphy. Antivir Ther. 2012; 17: 1021-7.
  • 19. Baranyi A, Meinitzer A, Putz-Bankuti C, et all. Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection. Psychosom Med. 2014; 76: 197-207.
  • 20. Mengeloglu Z, Sünnetcioglu M, Tosun M, et al. High asymmetric dimethylaginine (ADMA) levels in patients with brucellosis. Inflammation. 2014; 37: 127-31.
  • 21. Sahin M, Arslan C, Naziroglu M, et al. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet’s disease. Ann Clin Lab Sci. 2006; 36: 449-54.
  • 22. Ferrero MC, Bregante J, Delpino MV, et al. Proinflammatory response of human endothelial cells to Brucella infection. Microbes Infect. 2011; 13: 852-61.
  • 23. Aydemir S, Eren H, Tekin IO, et all. Helicobacter pylori eradication lowers serum asymmetric dimethylarginine levels. Mediators Inflamm. 2010; 2010: 685903.
  • 24. Sunnetcioglu M, Mengeloglu Z, Baran AI, et all. Asymmetric dimethylarginine levels in patients with cutaneous anthrax: a laboratory analysis. Ann Clin Microbiol Antimicrob. 2014; 13: 12.
  • 25. Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, et all. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection. PLoS One. 2014; 9: e90541.
  • 26. Parlak M, Akbayram S, Doğan M, et al. Clinical manifestations and laboratory findings of 496 children with brucellosis in Van, Turkey. Pediatr Int. 2015; 57: 586-9.
  • 27. Buzgan T, Karahocagil MK, Irmak H, et all. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis. 2010; 14: 469-78.
  • 28. Tanir G, Tufekci, SB, Tuygun N. Presentation, complications, and treatment outcome of brucellosis in Turkish children. Pediatr Int. 2009; 51: 114-9.
Year 2019, Volume: 46 Issue: 3, 479 - 487, 16.09.2019
https://doi.org/10.5798/dicletip.620502

Abstract

References

  • 1. Böger RH, Ron ES. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev. 2005; 10: 14-23.
  • 2. Böger RH. The emerging role of asymmetric dimethyarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003; 59: 824-33.
  • 3. Cooke JP. ADMA: its role in vascular disease. Vasc Med. 2005; 10: 11-7.
  • 4. Sitar ME, Kayacelebi AA, Beckmann B, Kielstein JT, Tsikas D. Asymmetric dimethylarginine (ADMA) in human blood: effects of extended haemodialysis in the critically ill patient with acute kidney injury, protein binding to human serum albumin and proteolysis by thermolysin. Amino Acids. 2015; 47: 1983-93.
  • 5. Teerlink T. ADMA metabolism and clearance. Vasc Med. 2005; 10: 73-81.
  • 6. Tain YL, Hsu CN. Toxic Dimethylarginines: Asymmetric Dimethlyarginine (ADMA) and Symmetric Dimethylarginine (SDMA). Toxins (Basel). 2017; 9: 92.
  • 7. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl. 2003; 4: 41-51.
  • 8. Gwida M, Al Dahouk S, Melzer F, et all. Brucellosis – regionally emerging zoonotic disease? Croat Med J. 2010; 51: 289-95.
  • 9. El-Koumi MA, Afify M, Al-Zahrani SH. A prospective study of brucellosis in children: relative frequency of pancytopenia. Mediterr J Hematol Infect Dis. 2013; 5: e2013011.
  • 10. Dede G, Dede O, Kapmaz M, Haykır Solay A, Utangaç M. Two cases of brucellosis epididymo-orchitis. Dicle Med J. 2015; 42 : 80-82.
  • 11. Ulu-Kilic A, Metan G, Alp E. Clinical presentations and diagnosis of brucellosis. Recent Pat Antiinfect Drug Discov. 2013; 8: 34-41.
  • 12. Dizbay M, Hizel K, Kilic S, et all. Brucella peritonitis and leucocytoclastic vasculitis due to Brucella melitensis. Braz J Infect Dis. 2007; 11: 443-44.
  • 13. Karahocagil MK, Aslan M, Ceylan MR, et all. Serum myeloperoxidase activity and oxidative stress in patients with acute brucellosis. Clin Biochem. 2012; 45: 733-6.
  • 14. Smith CL, Anthony S, Hubank M, Leiper JM, Vallance P. Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. PLoS Med. 2005; 2: e264.
  • 15. Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des. 2008; 14: 2613-8.
  • 16. Weis M, Kledal TN, Lin KY, et all. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation. 2004; 109: 500-5.
  • 17. Karakecili F, Cikman A, Aydin M, Gulhan B. Asymmetrical dimethylarginine levels in Hepatitis B virus-positive patients. Ann Lab Med. 2018; 38: 446-9.
  • 18. Kurz K, Teerlink T, Sarcletti M, et all. Asymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral theraphy. Antivir Ther. 2012; 17: 1021-7.
  • 19. Baranyi A, Meinitzer A, Putz-Bankuti C, et all. Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection. Psychosom Med. 2014; 76: 197-207.
  • 20. Mengeloglu Z, Sünnetcioglu M, Tosun M, et al. High asymmetric dimethylaginine (ADMA) levels in patients with brucellosis. Inflammation. 2014; 37: 127-31.
  • 21. Sahin M, Arslan C, Naziroglu M, et al. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet’s disease. Ann Clin Lab Sci. 2006; 36: 449-54.
  • 22. Ferrero MC, Bregante J, Delpino MV, et al. Proinflammatory response of human endothelial cells to Brucella infection. Microbes Infect. 2011; 13: 852-61.
  • 23. Aydemir S, Eren H, Tekin IO, et all. Helicobacter pylori eradication lowers serum asymmetric dimethylarginine levels. Mediators Inflamm. 2010; 2010: 685903.
  • 24. Sunnetcioglu M, Mengeloglu Z, Baran AI, et all. Asymmetric dimethylarginine levels in patients with cutaneous anthrax: a laboratory analysis. Ann Clin Microbiol Antimicrob. 2014; 13: 12.
  • 25. Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, et all. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection. PLoS One. 2014; 9: e90541.
  • 26. Parlak M, Akbayram S, Doğan M, et al. Clinical manifestations and laboratory findings of 496 children with brucellosis in Van, Turkey. Pediatr Int. 2015; 57: 586-9.
  • 27. Buzgan T, Karahocagil MK, Irmak H, et all. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis. 2010; 14: 469-78.
  • 28. Tanir G, Tufekci, SB, Tuygun N. Presentation, complications, and treatment outcome of brucellosis in Turkish children. Pediatr Int. 2009; 51: 114-9.
There are 28 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Research Article
Authors

Muhammed Sezgin This is me 0000-0003-2589-9668

Merve Aydın 0000-0002-1522-6083

Faruk Karakeçili This is me 0000-0002-7368-7187

Aytekin Çıkman This is me 0000-0001-9259-7091

Barış Gülhan This is me 0000-0002-2605-1282

Yusuf Kemal Arslan This is me 0000-0003-1308-8569

Publication Date September 16, 2019
Submission Date March 20, 2019
Published in Issue Year 2019 Volume: 46 Issue: 3

Cite

APA Sezgin, M., Aydın, M., Karakeçili, F., Çıkman, A., et al. (2019). Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması. Dicle Tıp Dergisi, 46(3), 479-487. https://doi.org/10.5798/dicletip.620502
AMA Sezgin M, Aydın M, Karakeçili F, Çıkman A, Gülhan B, Arslan YK. Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması. diclemedj. September 2019;46(3):479-487. doi:10.5798/dicletip.620502
Chicago Sezgin, Muhammed, Merve Aydın, Faruk Karakeçili, Aytekin Çıkman, Barış Gülhan, and Yusuf Kemal Arslan. “Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması”. Dicle Tıp Dergisi 46, no. 3 (September 2019): 479-87. https://doi.org/10.5798/dicletip.620502.
EndNote Sezgin M, Aydın M, Karakeçili F, Çıkman A, Gülhan B, Arslan YK (September 1, 2019) Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması. Dicle Tıp Dergisi 46 3 479–487.
IEEE M. Sezgin, M. Aydın, F. Karakeçili, A. Çıkman, B. Gülhan, and Y. K. Arslan, “Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması”, diclemedj, vol. 46, no. 3, pp. 479–487, 2019, doi: 10.5798/dicletip.620502.
ISNAD Sezgin, Muhammed et al. “Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması”. Dicle Tıp Dergisi 46/3 (September 2019), 479-487. https://doi.org/10.5798/dicletip.620502.
JAMA Sezgin M, Aydın M, Karakeçili F, Çıkman A, Gülhan B, Arslan YK. Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması. diclemedj. 2019;46:479–487.
MLA Sezgin, Muhammed et al. “Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması”. Dicle Tıp Dergisi, vol. 46, no. 3, 2019, pp. 479-87, doi:10.5798/dicletip.620502.
Vancouver Sezgin M, Aydın M, Karakeçili F, Çıkman A, Gülhan B, Arslan YK. Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması. diclemedj. 2019;46(3):479-87.